Skip to main content
Print Save

Generic Vtama Availability

Last updated on Nov 7, 2023.

Vtama is a brand name of tapinarof topical, approved by the FDA in the following formulation(s):

VTAMA (tapinarof - cream;topical)

  • Manufacturer: DERMAVANT SCI
    Approval date: May 23, 2022
    Strength(s): 1% [RLD]

Has a generic version of Vtama been approved?

No. There is currently no therapeutically equivalent version of Vtama available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vtama. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Topical pharmaceutical compositions
    Patent 10,195,160
    Issued: February 5, 2019
    Inventor(s): Sonti Sujatha D. & Thomas Joey Roger & Lenn Jon & Santos Leandro & Whiteman Justin & Doherty Michael Quinn & Bedard Mary & Jain Piyush
    Assignee(s): Dermavant Sciences GmbH

    The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.

    Patent expiration dates:

    • May 19, 2036
      ✓ 
      Drug product
  • Topical pharmaceutical compositions
    Patent 10,426,743
    Issued: October 1, 2019
    Inventor(s): Sonti Sujatha D. & Thomas Joey Roger & Lenn Jon & Santos Leandro & Whiteman Justin & Doherty Michael Quinn & Bedard Mary & Jain Piyush
    Assignee(s): DERMAVANT SCIENCES GMBH

    The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.

    Patent expiration dates:

    • May 19, 2036
      ✓ 
      Patent use: TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
  • Process for preparing tapinarof
    Patent 10,647,649
    Issued: May 12, 2020
    Inventor(s): Andrews Ian Paul & Calandra Nicholas & Davis Tyler Andrew & Sudini Ravinder Reddy
    Assignee(s): DERMAVANT SCIENCES GMBH

    The present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and novel intermediates used therein. In some embodiments the 3, 5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro-2-isopropyl-5-styrylcyclohexane-1,3-dione. Also disclosed are crystal forms of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and pharmaceutical compositions comprising same.

    Patent expiration dates:

    • November 13, 2038
      ✓ 
      Drug substance
  • Patent 11,458,108
    Issued: November 30, -0001

    Patent expiration dates:

    • May 19, 2036
      ✓ 
      Drug product
  • Patent 11,590,088
    Issued: November 30, -0001

    Patent expiration dates:

    • November 13, 2039
      ✓ 
      Patent use: TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
  • Patent 11,597,692
    Issued: November 30, -0001

    Patent expiration dates:

    • November 13, 2038
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Patent 11,612,573
    Issued: November 30, -0001

    Patent expiration dates:

    • May 19, 2036
      ✓ 
      Patent use: TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
  • Patent 11,617,724
    Issued: November 30, -0001

    Patent expiration dates:

    • May 19, 2036
      ✓ 
      Drug product
  • Patent 11,622,945
    Issued: November 30, -0001

    Patent expiration dates:

    • May 19, 2036
      ✓ 
      Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • May 23, 2027 - NEW CHEMICAL ENTITY

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer